MONMOUTH JUNCTION, N.J., July 19, 2018 /PRNewswire/ -- DiamiR, a developer of innovative minimally invasive diagnostic testsfor neurodegenerative and other diseases, today announced that it will exhibit at the Alzheimer's Association International Conference to be held in Chicago, IL on July 22-26, 2018.
About Alzheimer's Association International Conference The Alzheimer's Association International Conference (AAIC) is the world's largest gathering of researchers from around the world focused on Alzheimer's and other dementias. As a part of the Alzheimer's Association's research program, AAIC serves as a catalyst for generating new knowledge about dementia and fostering a vital, collegial research community.
About DiamiRDiamiR Biosciences is a privately held molecular diagnostics company focused on developing minimally invasive tests for mild cognitive impairment, Alzheimer's disease, and other conditions. The proprietary technology is based on quantitative analysis of organ-enriched microRNA signatures in plasma and is being developed for early diagnosis, patient stratification, as well as disease progression and treatment monitoring. DiamiR collaborates with leading academic centers, disease foundations, and pharma companies. For more information, please visit the company's website at www.diamirbio.com.
Contact: Kira Sheinerman, PhD, MBACEO917email@example.com
Please Note: This news release contains forward-looking statements regarding future events. These statements are predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially.
View original content:http://www.prnewswire.com/news-releases/diamir-announces-participation-at-2018-alzheimers-association-international-conference-300683500.html
Subscribe to our Free Newsletters!
Collagen plays a crucial role in glowing skin, strong nails and shiny hair. You can boost collagen ...
CRISPR technology is a simple but potent tool for editing any part of the genome (complete set of ...
FDA recently approved Mogamulizumab-kpkc, a human monoclonal antibody prescribed for adult ...View All